The region had given its data but could not access the medicines made from it.
From a research center in Pernambuco, two scientists have placed a quiet but consequential argument before the world: the genetic material of Latin America and the Caribbean is not a gift freely given, but a resource whose value has long flowed in one direction. During the COVID-19 pandemic, the region offered its biology and its people to the global scientific effort, yet found itself waiting while others reaped the harvest. The call now is not for walls, but for reciprocity — a renegotiation of the terms by which knowledge is shared and benefit is returned.
- Latin America and the Caribbean contributed genomic data and clinical trial participants during COVID-19, only to face delays in accessing the vaccines and diagnostics built from their contributions.
- The structural imbalance is stark: wealthy nations hold the technological infrastructure while developing countries supply the biological raw material, rendering their contributions invisible once a product reaches market.
- Fiocruz researchers Gabriel da Luz Wallau and Túlio de Lima Campos are pushing back, publishing in The Lancet Regional Health – Americas a formal case for genomic sovereignty as a matter of health equity.
- Their proposal would make genomic data sharing conditional — tied explicitly to technology transfer, local capacity-building, and meaningful participation in intellectual property decisions.
- Regional blocs CELAC, Mercosur, and CARICOM, alongside PAHO, are named as the institutions capable of turning this framework from argument into policy.
- The trajectory points toward a redefined global health compact — one where data-sharing is an act of power-sharing, not charity.
Researchers at Brazil's Oswaldo Cruz Foundation have published a pointed challenge in The Lancet Regional Health – Americas: the genetic material flowing out of Latin America and the Caribbean deserves to be treated as leverage, not largesse. Gabriel da Luz Wallau and Túlio de Lima Campos, working at Fiocruz's Pernambuco campus, ground their argument in the lived experience of the COVID-19 pandemic, when the region contributed biological samples, viral genome sequences, and clinical trial participants to the global response — and then waited as wealthier nations, controlling manufacturing and diagnostic technology, moved first to protect their own populations.
The asymmetry Túlio describes is structural, not accidental. Developing nations supply the raw material — the genomes, the real-world evidence, the human data — but do not quickly or fully benefit from what is built with it. Once a product is finished, the original contribution disappears from the story.
The researchers' answer is what they call genomic sovereignty: a regional agenda in which major blocs — CELAC, Mercosur, CARICOM — working with the Pan-American Health Organization, would make data sharing conditional on concrete returns. Rapid access to genomic information would come attached to demands for technology transfer, investment in local sequencing and bioinformatics capacity, support for regional manufacturing, and genuine participation in decisions about intellectual property.
This is not a call for protectionism. It is a call for reciprocity — a reframing of the entire transaction so that nations move from being sources of raw material to partners in the knowledge and products that follow. The question the article leaves open is whether the regional organizations it names will take up the challenge before the next pandemic makes the cost of inaction undeniable.
A group of researchers at Brazil's Oswaldo Cruz Foundation has published a pointed argument in The Lancet Regional Health – Americas: the genetic material flowing out of Latin America and the Caribbean should not be treated as a simple gift to the world. It should be treated as leverage.
The article, appearing in the journal's June issue, comes from Gabriel da Luz Wallau and Túlio de Lima Campos, both working in the Bioinformatics Center at Fiocruz's Pernambuco campus. Their central observation is straightforward but damning. During the COVID-19 pandemic, countries across the region contributed biological samples, genetic data, and thousands of people willing to participate in clinical trials. Researchers sequenced viral genomes. Public health systems tracked variants. The region became, in effect, a laboratory for the world.
What followed was a familiar pattern. While wealthy nations that controlled vaccine manufacturing and diagnostic technology moved quickly to protect their populations, Latin America and the Caribbean waited. The delays were not incidental. They were structural. The same genetic information that flowed north—freely shared in the name of global health—did not flow back as finished products, as manufacturing capacity, as the tools needed to respond independently to the next outbreak. The region had given its data but could not access the medicines made from it.
Túlio explains the asymmetry with precision: there exists a fundamental imbalance between countries that own the technological infrastructure and those that own the biological samples. Developing nations provide the raw material—the genomes, the clinical information, the real-world evidence—but do not fully or quickly benefit from what researchers build with it. The contribution becomes invisible once the product is finished.
The researchers propose something more ambitious than complaint. They call for what they term genomic sovereignty—a regional agenda in which major Latin American and Caribbean blocs, including CELAC, Mercosur, and CARICOM, working alongside institutions like the Pan-American Health Organization, would fundamentally reshape how genetic data moves across borders. The idea is to make data sharing conditional. Rapid access to genomic information would no longer be automatic. Instead, it would come with explicit demands: technology transfer from the companies and wealthy nations that benefit from the data. Investment in local sequencing capacity and bioinformatics expertise. Support for regional manufacturing of diagnostics and therapeutics. Real participation in decisions about intellectual property and data use.
The proposal reframes the entire transaction. Sharing genetic data would become, in this model, a form of power-sharing. Nations would move from being sources of raw material to being partners in the creation and distribution of the knowledge and products that follow. The goal is not isolation but equity—ensuring that when the next pandemic arrives, or the next genetic discovery is made, the countries that contributed the data are not waiting in line for access to what they helped create.
This is not a call for secrecy or protectionism. It is a call for reciprocity. The researchers are arguing that global health cooperation, to be truly global, must benefit the regions that make it possible. The question now is whether the regional organizations they name will take up the challenge.
Citações Notáveis
This fact reveals the inequalities between countries that control technologies versus developing countries that hold genetic samples and information, who end up unable to fully and quickly benefit from products created from their research and monitoring efforts.— Túlio de Lima Campos, Fiocruz Pernambuco
A Conversa do Hearth Outra perspectiva sobre a história
Why does it matter whether genomic data is called a "public good" versus a "strategic asset"?
Because the name determines who controls what happens next. If data is a public good, it flows freely, and whoever has the technology to use it keeps the advantage. If it's strategic, you can say: you want our data, you invest in our capacity.
But doesn't sharing data faster save lives? Wouldn't restricting it slow down research?
That's the tension. Yes, speed matters in a pandemic. But the researchers are saying: speed for whom? Latin America shared fast during COVID and still waited months for vaccines. They're asking why the speed only flows one direction.
What would actually change if a country refused to share genomic data?
Probably very little, at first. But if CELAC, Mercosur, and CARICOM moved together, they'd represent a significant portion of global genetic diversity. You can't ignore that. The leverage is real, but only if they use it together.
Is this about money, or about capability?
Both. Money funds the labs and equipment. But capability is the deeper issue. If you can't sequence your own genomes or manufacture your own diagnostics, you're dependent. The researchers want to flip that.
What happens to the next pandemic if countries start hoarding data?
That's the risk they're taking. But they'd argue it's already happening—wealthy countries hoarded vaccines while others died. At least this way, the regions that contribute data would have the tools to respond themselves.